UK markets close in 23 minutes

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.54500.0000 (0.00%)
As of 04:05PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.5450
Open0.5450
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.5450 - 0.5450
52-week range0.5450 - 2.6000
Volume105
Avg. volume1
Market cap21.038M
Beta (5Y monthly)1.52
PE ratio (TTM)N/A
EPS (TTM)-1.1700
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update

    LYON, France, February 15, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2023.

  • Business Wire

    Poxel Announces its Financial Calendar for 2024

    LYON, France, January 03, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024.

  • Business Wire

    Poxel Provides Corporate Update

    LYON, France, December 21, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, provides a corporate update.